Product image of Medialipide (Soya-Bean Oil Refined, Triglycerides, Medium Chain) supplied by GNH India

Medialipide

Active Ingredient:
Soya-Bean Oil Refined, Triglycerides, Medium Chain
Origin:
EU

Medialipide (Soya-Bean Oil Refined, Triglycerides, Medium Chain)

Soya-Bean Oil Refined, Medium Chain Triglycerides, the active ingredient in Medialipide, is an excipient presented as an intravenous solution for intravenous use. It provides a source of medium-chain fatty acids and serves as a lipid carrier in parenteral formulations.

GNH India supplies Medialipide as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

B.Braun Medical Sas

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Medialipide, containing medium-chain triglycerides, is used as a lipid component in intravenous nutrition and drug delivery systems.
  • Parenteral nutrition: supplies calories and essential fatty acids for patients requiring intravenous feeding.
  • Lipid-based drug formulations: acts as a solubilizing vehicle for fat‑soluble medications administered intravenously.
  • Organ transplantation support: provides an energy substrate in post‑operative IV regimens.

How It Works

  • Medium-chain triglycerides in Medialipide are hydrolyzed by plasma lipases to medium-chain fatty acids, which are rapidly taken up by the liver and oxidized for energy. The resulting fatty acids also integrate into lipid micelles, enhancing the solubility and stability of co‑administered lipophilic drugs, thereby facilitating their intravenous delivery.

Side Effects

Medialipide may be associated with several adverse reactions when administered intravenously.

Common Side Effects

  • Hypertriglyceridemia: mild elevation of serum triglyceride levels.
  • Infusion site reactions: erythema, warmth, or mild pain at the catheter site.
  • Transient fever: low‑grade temperature rise during infusion.
  • Nausea or mild gastrointestinal discomfort.
  • Headache: occasional mild headache during or after infusion.
  • Allergic rash: skin erythema or urticaria.

Serious or Rare Side Effects

  • Anaphylaxis: severe hypersensitivity requiring immediate medical intervention.
  • Fat overload syndrome: accumulation of lipids leading to organ dysfunction.
  • Hepatic dysfunction: elevated liver enzymes or hepatic steatosis.
  • Acute pancreatitis: inflammation of the pancreas.
  • Embolism: lipid emboli causing respiratory or circulatory compromise.
  • Severe hypotension: sudden drop in blood pressure during infusion.

Precautions & Warnings

  • When using Medialipide, clinicians should observe specific safety measures.
  • Patient assessment: evaluate lipid tolerance and baseline triglyceride levels.
  • Monitoring: check serum triglycerides and liver enzymes during therapy.
  • Allergy screening: assess for soy or lipid emulsion hypersensitivity.
  • Dose adjustment: modify in patients with impaired fatty acid oxidation.
  • Compatibility: verify compatibility with co‑administered drugs.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Medialipide can interact with other medications, requiring careful management.

Major Interactions (Avoid)

  • Propofol: additive lipid load may cause fat overload.
  • Corticosteroids: can increase triglyceride concentrations.
  • Heparin: may potentiate hypertriglyceridemia.

Moderate Interactions (Monitor Closely)

  • Vincristine: lipid emulsion may alter drug distribution.
  • Cyclosporine: monitor liver function due to combined hepatic load.
  • Statins: watch for additive hepatic effects.

Frequently Asked Questions

Medialipide is an intravenous lipid excipient containing refined soy‑bean oil and medium‑chain triglycerides. It is employed as a source of calories and essential fatty acids in parenteral nutrition and as a solubilizing carrier for lipophilic drugs administered by infusion.

The medium‑chain triglycerides are hydrolyzed by circulating lipases to medium‑chain fatty acids, which are rapidly oxidized for energy. These fatty acids also form micellar structures that improve the solubility and stability of co‑administered lipophilic compounds during intravenous delivery.

The dosing of Medialipide is determined by the prescribing clinician based on the patient’s nutritional needs, lipid tolerance, and the specific therapeutic protocol. No fixed regimen is provided; the prescriber sets the appropriate volume and rate of infusion.

Safety data for Medialipide in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against any theoretical risks and consider alternative nutrition strategies if safer options are available.

To request Medialipide, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with long‑chain triglyceride emulsions, Medialipide’s medium‑chain profile is metabolized more rapidly, offering quicker energy delivery and reduced risk of lipid accumulation. It may be preferred when a faster‑acting lipid source or enhanced solubilization of lipophilic drugs is required.

Medialipide should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or vigorously shake the solution, as this can compromise emulsion stability.

Medialipide is administered intravenously, either as a continuous infusion for nutritional support or as a bolus when used as a drug‑solubilizing carrier. Administration should follow aseptic technique and be compatible with the infusion equipment used.

Serious risks include anaphylactic reactions, fat overload syndrome, hepatic dysfunction, acute pancreatitis, lipid embolism, and severe hypotension. Prompt recognition and management of these events are essential during infusion.

Patients with known hypersensitivity to soy products, severe hypertriglyceridemia, impaired fatty‑acid oxidation disorders, or those who have experienced previous lipid‑emulsion reactions should avoid Medialipide unless a risk‑benefit assessment justifies its use.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Soya-Bean Oil Refined, Triglycerides, Medium Chain

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT